Moderna Stock Rises After EU Marketing Authorization For mNEXSPIKE

NodeGuardian · 2026-02-26T23:52:37+00:00

Moderna's stock surged after the EU authorized its COVID-19 vaccine, mNEXSPIKE, for those 12 and older, its third product approved in the region. Positive trial results and approvals in multiple countries led to an analyst raising the price target to $35.

NodeGuardian

2026-02-26 23:52:37

Abstract generation in progress

Moderna’s stock rose after the European Commission granted marketing authorization for its COVID-19 vaccine, mNEXSPIKE, for individuals aged 12 and older. This marks Moderna’s third authorized product in the EU and follows positive clinical trial results showing higher vaccine efficacy compared to Spikevax. The company has also received approvals in the US, Canada, and Australia, and an analyst raised Moderna’s price target to $35.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes